Predictors of Inadequate 24-Hour Sustained Response in Episodic Migraine: Results from American Migraine Prevalence and Prevention Study (AMPP) (I3.013)

CONCLUSIONS: Among migraineurs reporting 2hPF, adequate 24hSPR was common (74.3[percnt]). However, 25.7[percnt] reported return of headache. Persons with frequent headache, allodynia, depression and medication overuse may be susceptible to return of headache despite a robust 2hPF response. Study Supported By: Promius PharmaDisclosure: Dr. Munjal has received personal compensation for activities with Promius Pharma as an employee. Dr. Reed has received personal compensation for activities with Allergan, Inc., Colucid, Endo Pharmaceuticals, GlaxoSmithKline, Merck & Co., Inc., NuPathe, Novartis, and Ortho-McNeil. Dr. Buse has received personal compensation for activities with Allergan, Avanir, and Eli Lilly. Dr. Buse has received research support from Allergan and Avanir. Dr. Bennett has received personal compensation for activities with Dr. Reddy's Laboratories/Promius Pharmaceutical company as an employee. Dr. Fanning has received personal compensation for activities with Allergan, Inc., Endo Pharmaceuticals, GlaxoSmithKline, MAP Pharmaceuticals, Merck & Co., Inc., NuPathe, Novartis, and Ortho-McNeil. Dr. Lipton has received personal compensation for activities with Allergan, American Headache Society, Autonomic Technologies, Boston Scientific, Bristol Myers Squibb, Cognimed, Colucid, Eli-Lilly, eNeura Therapeutics, Merck, Novartis, Pfizer, Teva, and V

Source: Neurology - April 3, 2016 Category: Neurology Authors: Munjal, S., Reed, M., Buse, D., Bennett, A., Fanning, K., Lipton, R. Tags: New and Emerging Therapeutic Options in Migraine and Other Headache Disorders Poster Presentations Source Type: research